Last reviewed · How we verify
H1 Receptor Antagonist
H1 receptor antagonists block histamine binding to H1 receptors, reducing histamine-mediated allergic and inflammatory responses.
H1 receptor antagonists block histamine binding to H1 receptors, reducing histamine-mediated allergic and inflammatory responses. Used for Allergic rhinitis, Urticaria, Allergic reactions.
At a glance
| Generic name | H1 Receptor Antagonist |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | H1 receptor antagonist |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
H1 receptor antagonists competitively inhibit histamine at H1 receptors located on smooth muscle, endothelial cells, and immune cells. This blocks histamine-induced effects such as vasodilation, increased vascular permeability, smooth muscle contraction, and itching. They are commonly used to treat allergic reactions, urticaria, and allergic rhinitis.
Approved indications
- Allergic rhinitis
- Urticaria
- Allergic reactions
- Pruritus
Common side effects
- Drowsiness/sedation
- Dry mouth
- Headache
- Dizziness
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (PHASE3)
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H1 Receptor Antagonist CI brief — competitive landscape report
- H1 Receptor Antagonist updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI